Prestige Consumer Healthcare Inc.
Close on Oct 19, 2026
- Market cap
- $2.37B
- P/E (TTM)
- 13.9
- Dividend yield
- –
About Prestige Consumer Healthcare
Pharmaceutical Preparations, SIC 2834
Prestige Consumer Healthcare Inc. develops, manufactures, markets, and distributes over-the-counter healthcare and personal care products. The company's offerings include pain relievers, gastrointestinal remedies, sore throat medications, eye and ear care items, dermatological treatments, oral care products, and feminine hygiene supplies. It organizes operations into two reporting segments: North American OTC Healthcare and International OTC Healthcare. Its customers consist of retail and wholesale businesses, including mass merchandisers, drugstores, supermarkets, dollar and convenience stores, club stores, and e-commerce merchants.
The company sells its merchandise across North America, particularly the United States and Canada, as well as Australia and select global markets. It operates three manufacturing plants in the United States, Canada, and Australia, while handling distribution within the continental United States through one contracted facility. It also utilizes 95 third-party contract manufacturers, primarily based in North America. The provided document indicates Delaware incorporation but does not mention the location of its headquarters.
Summary of the business section of Prestige Consumer Healthcare's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Prestige Consumer Healthcare Inc.
- Founded
- 1996
- Headquarters
- Tarrytown, NY
- Address
- 660 White Plains Rd. 10591
- Phone
- (914) 524-6800
- Website
- www.prestigebrands.com
- Employees
- 890, Mar 31, 2026
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- March 31
- Auditor
- PricewaterhouseCoopers LLP, Stamford, Connecticut
Stock & identifiers
- Ticker
- PBH
- Exchange
- NYSE
- IPO date
- Feb 11, 2005
- Shares outstanding
- 47M, Jul 31, 2026
- Public float
- $2.97B, Sep 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1295947
- CUSIP
- 74112D101
- ISIN
- US74112D1019
- EIN
- 20-1297589
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ronald M. Lombardi | Chief Executive Officer, Director | 373,465 |
| Christine Sacco | CFO & COO | 57,374 |
| Jeffrey Zerillo | Senior VP Operations | 41,810 |
| Adel Mekhail | EVP, Marketing & Sales | 25,703 |
| William P'Pool | See Remarks | 28,249 |
| Jose Luis Rosado | See Remarks | 10 |
| Mary Beth Fritz | SVP Quality & Regulatory | 17,051 |
| John F. Kelly | Director | 7,832 |
| James DArecca | Director | 9,572 |
| Celeste A. Clark | Director | 16,511 |
| Dawn M. Zier | Director | 19,514 |
| John E. Byom | Director | 54,575 |
| Sheila Hopkins | Director | 30,123 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Mr. Lombardi | $6.00M | $825.50K | $1.57M | $134 | $70 |
| FY2025 Mr. Lombardi | $6.19M | $7.58M | $1.90M | $195 | $114 |
| FY2024 Mr. Lombardi | $5.76M | $9.71M | $1.38M | $165 | $100 |
| FY2023 Mr. Lombardi | $5.58M | $9.54M | $1.35M | $142 | $88 |
| FY2022 Mr. Lombardi | $6.03M | $9.91M | $1.51M | $120 | $100 |
| FY2021 Mr. Lombardi | $5.15M | $6.12M | $1.24M | $120 | $158 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had approximately 890 global employees.”
Corporate history
Events identified from SEC filings